FibroGen Hails 'Milestone' IPF Data, Phase III And Partners Beckon
Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have potential partners scrambling.
You may also be interested in...
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
Finance Watch: 2Q Brings Cost Cuts, Strategic Reviews For Many Biotechs
Peregrine, Ardelyx, Egalet and others reduced expenses and sought alternatives in the second quarter. Also, cell and gene therapy investment rises, FibroGen priced a $326m offering and Unity increased its Series B by $35m.